Further clinical studies exploring the beneficial influence of therapy in CKD (vitamin D, iron replacement, anemia treatment, etc.)and the association to FGF-23 and sclerostin levels with the cardiovascular outcome, would be of great help in understanding the complex pathophysiological mechanism of CKD-MBD. Here, FGF23 is linked to chronic kidney disease.